Seeking Adults with Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma


17161

Phase I Trial of Pomalidomide for Patients with Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Neurology

Schiff David,

Seeking Adults with Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma UVA Health System seeks men and women, 18 and older, with Central Nervous System Lymphoma (CNSL) or Primary Vitreoretinal Lymphoma (PVRL) to participate in a clinical research study. Your lymphoma must have either not responded to treatment or have come back following treatment. This is a phase I trial that aims to find the maximal tolerated dose and side effects of pomalidomide in this patient population. Pomalidomide is investigational, meaning it is not FDA-approved for this use. Initial treatment for CNSL typically consists of high-dose methotrexate-based chemotherapy with or without radiation therapy. Initial treatment for PVRL is usually radiation therapy, intravitreal chemotherapy, or high-dose methotrexate chemotherapy. PVRL often relapses in the central nervous system. Should you agree to participate and your doctor determines you are eligible to enroll; you will be treated with the investigational drug called Pomalidomide. You will take the study drug by mouth daily for 21 days out of each 28 day cycle. You will continue taking the study drug as long as you do not experience significant tumor growth or have unacceptable drug effects. You or your physician may also choose to stop treatment at any time. Participants in this study will have routine medical and physical exams performed as well as tumor evaluations done by MRI or CT. Other standard care may include: routine blood tests, bone marrow biopsy and aspirate, EKG, eye evaluation, pregnancy test, HIV and hepatitis testing, CSF testing, and an aspirin/steroid regimen. Participants may choose to donate blood, CSF and tissue for the research. You will not receive any payment or compensation for participating in this study. The study drug will be provided free of charge and you and your insurance will not be charged for samples that are collected for research purposes only. For more information or to see if you qualify to take part in this study, please contact: Contact: Heather Tribout Clinical Research coordinator Neuro-Oncology Phone: (434)-243-9360 Email: hjt3f@virginia.edu Primary Investigator: David Schiff, MD IRB-HSR# 17161


Adult

Lymphomas

Neurosurgery
Neuro-Oncology
Cancer (Oncology)

Ill

No Compensation

Heather Tribout

hjt3f@virginia.edu

4342439360